Theraclion

Theraclion is a French medical technology company that develops and commercializes noninvasive therapeutic solutions using high-intensity focused ultrasound (HIFU). Founded around 2004 as a spin-off from EDAP-TMS, the company is headquartered in Malakoff, France, and employs about 30 people. Theraclion focuses on research and development, particularly in clinical trials. The company's flagship product is the ECHOPULSE® platform, a robotic HIFU system designed for the noninvasive treatment of thyroid nodules and benign breast tumors. This technology has been CE marked since 2009 for thyroid nodules and expanded to include breast fibroadenomas in 2012. Theraclion also offers the SONOVEIN® device, approved in Europe for treating varicose veins. The company is exploring new treatment indications, including breast cancer, and is planning to expand into the U.S. market while targeting growth in Asia, particularly for thyroid treatments. Theraclion collaborates with hospitals, clinics, and academic institutions to enhance clinical research and therapeutic applications.

• Employees 28
• Founded 2004
• Annual Revenue $864000
• Total Funding $15749980